Spots Global Cancer Trial Database for braf v600e
Every month we try and update this database with for braf v600e cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| ENCOrafenib With Binimetinib in bRAF NSCLC | NCT04526782 | Non Small Cell ... BRAF V600E | Encorafenib 75 ... Binimetinib 15 ... | 18 Years - | Intergroupe Francophone de Cancerologie Thoracique | |
| Dabrafenib and Trametinib in Patients With Non-small Cell Lung Cancer Harboring V600E BRAF Mutation | NCT03543306 | Cancer Lung Cancer Met... BRAF V600E | daborafenib plu... | 18 Years - | Asan Medical Center | |
| Overcoming Primary Resistance to Immunotherapy in Metastatic Melanoma | NCT05304546 | Malignant Melan... Metastatic Mela... Immunotherapy BRAF V600E Malignant Melan... | Pembrolizumab Encorafenib Binimetinib | 18 Years - | Sheba Medical Center | |
| A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer. | NCT05004350 | BRAF V600E Metastatic Colo... | Encorafenib Cetuximab FOLFIRI | 18 Years - | Pierre Fabre Medicament | |
| A Retrospective Non Interventional Study on First Line Treatment for Patients With BRAFV600E Mutant Metastatic Colorectal Cancer (mCRC) | NCT04317599 | BRAF V600E Muta... Metastatic Colo... | Non Interventio... | 18 Years - | Pierre Fabre Medicament | |
| Dabrafenib and Trametinib in Patients With Non-small Cell Lung Cancer Harboring V600E BRAF Mutation | NCT03543306 | Cancer Lung Cancer Met... BRAF V600E | daborafenib plu... | 18 Years - | Asan Medical Center | |
| Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma | NCT01767454 | Solid Tumours | Dabrafenib Trametinib Ipilimumab | 18 Years - | GlaxoSmithKline | |
| A Study of Dabrafenib in Combination With Trametinib in Chinese Patients With BRAF V600E Mutant Metastatic NSCLC | NCT04452877 | Carcinoma, Non-... | Dabrafenib Trametinib | 18 Years - | Novartis | |
| A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations | NCT05503797 | Cancer Harborin... | Plixorafenib Cobicistat | 10 Years - | Fore Biotherapeutics | |
| A Basket Trial of an ERK1/2 Inhibitor (LY3214996) in Combination With Abemaciclib. | NCT04534283 | Cancer Cancer Metastat... BRAF V600E MEK1 Gene Mutat... MEK2 Gene Mutat... ERK Mutation RAF1 Gene Mutat... | Abemaciclib LY3214996 | 18 Years - | Indiana University | |
| Versatile Ampification Single-Molecule Detection in Liquid Biopsy | NCT05940311 | Liquid Biopsy Melanoma (Skin) Melanoma Stage ... Melanoma Stage ... BRAF V600E | Affinity Mediat... | 18 Years - | Regina Elena Cancer Institute | |
| Encorafenib, Binimetinib, and Nivolumab in Treating Microsatellite Stable BRAF V600E Metastatic Colorectal Cancer | NCT04044430 | Metastatic Colo... Metastatic Colo... Metastatic Micr... Metastatic Rect... Stage III Colon... Stage III Color... Stage III Recta... Stage IIIA Colo... Stage IIIA Colo... Stage IIIA Rect... Stage IIIB Colo... Stage IIIB Colo... Stage IIIB Rect... Stage IIIC Colo... Stage IIIC Colo... Stage IIIC Rect... Stage IV Colon ... Stage IV Colore... Stage IV Rectal... Stage IVA Colon... Stage IVA Color... Stage IVA Recta... Stage IVB Colon... Stage IVB Color... Stage IVB Recta... Stage IVC Colon... Stage IVC Color... Stage IVC Recta... | Binimetinib Encorafenib Nivolumab Questionnaire A... | 18 Years - | University of California, San Francisco | |
| An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer | NCT03915951 | Non-small Cell ... | encorafenib binimetinib | 18 Years - | Pfizer | |
| BRAF V600E Mutations In Papillary Thyroid Carcinoma | NCT01417442 | Papillary Thyro... | BRAF V600E POSI... | - | Bezmialem Vakif University | |
| Overcoming Primary Resistance to Immunotherapy in Metastatic Melanoma | NCT05304546 | Malignant Melan... Metastatic Mela... Immunotherapy BRAF V600E Malignant Melan... | Pembrolizumab Encorafenib Binimetinib | 18 Years - | Sheba Medical Center | |
| BRAF V600E Mutations In Papillary Thyroid Carcinoma | NCT01417442 | Papillary Thyro... | BRAF V600E POSI... | - | Bezmialem Vakif University | |
| A Retrospective Non Interventional Study on First Line Treatment for Patients With BRAFV600E Mutant Metastatic Colorectal Cancer (mCRC) | NCT04317599 | BRAF V600E Muta... Metastatic Colo... | Non Interventio... | 18 Years - | Pierre Fabre Medicament | |
| A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations | NCT05503797 | Cancer Harborin... | Plixorafenib Cobicistat | 10 Years - | Fore Biotherapeutics | |
| Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer. | NCT01336634 | Cancer | Dabrafenib Trametinib | 18 Years - | Novartis | |
| A Basket Trial of an ERK1/2 Inhibitor (LY3214996) in Combination With Abemaciclib. | NCT04534283 | Cancer Cancer Metastat... BRAF V600E MEK1 Gene Mutat... MEK2 Gene Mutat... ERK Mutation RAF1 Gene Mutat... | Abemaciclib LY3214996 | 18 Years - | Indiana University | |
| ZN-c3 in Adult Participants With Metastatic Colorectal Cancer | NCT05743036 | Metastatic Colo... | ZN-c3 Encorafenib Cetuximab | 18 Years - | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | |
| A Biospecimen Collection Study in BRAF-V600E Mutated Recurrent Gliomas | NCT03593993 | Glioma BRAF V600E Pleomorphic Xan... Glioblastoma | Surgical Cohort | 6 Weeks - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer. | NCT01336634 | Cancer | Dabrafenib Trametinib | 18 Years - | Novartis | |
| Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study) | NCT04585815 | Carcinoma, Non-... | Sasanlimab Pref... Encorafenib Binimetinib Sasanlimab Axitinib SEA-TGT | 18 Years - | Pfizer | |
| An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer | NCT03915951 | Non-small Cell ... | encorafenib binimetinib | 18 Years - | Pfizer | |
| A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer. | NCT05004350 | BRAF V600E Metastatic Colo... | Encorafenib Cetuximab FOLFIRI | 18 Years - | Pierre Fabre Medicament | |
| A Biospecimen Collection Study in BRAF-V600E Mutated Recurrent Gliomas | NCT03593993 | Glioma BRAF V600E Pleomorphic Xan... Glioblastoma | Surgical Cohort | 6 Weeks - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI Therapy | NCT03042221 | Non-Small Cell ... Non-Small Cell ... EGFR Gene Mutat... ALK Gene Mutati... ROSE Cluster 1 BRAF V600E | 18 Years - 85 Years | University of Colorado, Denver | ||
| Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD) | NCT03944772 | Non-Small Cell ... | Osimertinib Savolitinib Gefitinib Necitumumab Durvalumab Carboplatin Pemetrexed Alectinib Selpercatinib Selumetinib Etoposide Cisplatin Datopotamab der... | 18 Years - 130 Years | AstraZeneca | |
| ZN-c3 in Adult Participants With Metastatic Colorectal Cancer | NCT05743036 | Metastatic Colo... | ZN-c3 Encorafenib Cetuximab | 18 Years - | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
